Table 6 Predictors of cardiac, obstetric, and fetal events in literature
CAPREG I (8) | ROPAC REGISTRY [3] | CAPREG II [12] | Our Study | |
|---|---|---|---|---|
Study Period | 1994–1999 | 2008–2014 | 2001–2014 | 2010–2017 |
Publication year | 2001 | 2016 | 2018 | – |
Methodology | Prospective (Canadian registry) | Prospective (multicenter European Registry) | Prospective cohort (Canadian registry) | Retrospective cohort |
Population | N = 599 (congenital and acquired disease) | N = 2742,VHD = 865 | N = 1938 | N = 60 pregnancies in 54 women with severe valve disease, 61 newborns |
Age (years) | 28 ± 6 | 29.2 ± 5.5 | 30.6 ± 5.6 | 32.5 ± 5.6 |
MCC incidence | 13% | 20.6% | 16% | 61% |
Independent Predictors of MCC | *Cardiac disease antecedent *NYHA≥2 /cyanosis *Left heart obstruction *LVEF ≤40% | *Pre-pregnancy signs of heart failure *in advanced countries. Atrial fibrillation and no previous cardiac intervention | *Prior cardiac events or arrhythmias. *poor functional class or cyanosis. *high-risk valve disease/left ventricular outflow tract obstruction. *systemic ventricular dysfunction. *no prior cardiac interventions. *Mechanical valves. *high-risk aortopathies. *pulmonary hypertension. *late pregnancy assessement | *Parity *Revelation of the valve disease by pregnancy *Mitral stenosis *Systolic pulmonary hypertension |
OC incidence | 7% | 8.4% | – | 31% |
Independent Predictors of OC | *Primiparity *Aortic coarctation. *lupus *Anticoagulant use. *cyanosis | *Primiparity. *hypertension before pregnancy | – | *Nulliparity *PASP *Anticoagulant use *Multiple valve disease |
NC incidence | 20% | 23.7% | – | 39.3% |
Independent predictors of NC | Multigestity NYHA II or cyanosis Anticoagulant use Tobacco use Left heart obstruction | Multigestity Anticoagulant use Pregnancy in underdeveloped countries | – | Maternal cardiac complications Valve disease revealed by pregnancy |